Five biotech and healthcare stocks hit 52-week highs on October 9

what happened

According to dpa-AFX, shares of five biotechnology and healthcare companies reached 52-week highs on October 9, 2026. Humana Inc. (HUM) gained 11% intraday and touched $456.50. The move followed an improved Star Rating from the Centers for Medicare and Medicaid Services, with about 95% of the company’s Medicare Advantage members enrolled in plans rated 4 stars or higher. Humana also said it addressed 663,000 more care opportunities than a year earlier and expects Medicare Advantage membership to grow 25% in full-year 2026.

Puma Biotechnology Inc. (PBYI) rose more than 3% to $10.10. The company has licensed and commercialized Neratinib for HER2-overexpressed breast cancer and acquired Alisertib for small cell lung cancer and breast cancer. Alisertib is being evaluated in the Phase 2 ALISCA-Lung2 trial in combination with paclitaxel.

AbbVie Inc. (ABBV) reached $274.94 after reporting two Breakthrough Therapy designations from the FDA for Temab-A (ABBV-400) in colorectal cancer and non-small cell lung cancer. Its third-quarter results are scheduled for October 30, 2026. Moderna Inc. (MRNA) jumped 14% to $225 after positive Phase 3 INTerpath-001 data for Intismeran autogene combined with KEYTRUDA in Stage IIB-IV melanoma. The study, conducted with Merck (MRK), met its primary recurrence-free survival endpoint and a key secondary distant metastasis-free survival endpoint.

AVITA Medical Inc. (RCEL) climbed to $13.71. Second-quarter revenue increased 18% to $21.7 million, prompting the company to raise its 2026 guidance to $86 million-$89 million from $71.6 million in 2025. AVITA markets the FDA-approved RECELL therapy for thermal burn and trauma wounds, along with Cohealyx and PermeaDerm. On October 9, 1991, the FDA approved Didanosine, which became the second approved HIV treatment after AZT was approved in 1987.

why it matters

The moves highlight how clinical-trial results, regulatory designations, insurance ratings and revised company guidance can affect individual healthcare stocks. The market response differs according to each issuer’s business and development pipeline.

instruments